Exscientia Plc (EXAI) has released an update.
Exscientia Plc is set to revolutionize drug discovery by merging with Recursion Pharmaceuticals, aiming to enhance the development of novel treatments through advanced technology. They’ve made significant headway in their proprietary pipeline, particularly with their CDK7 inhibitor ‘617, expecting Phase I data in the latter half of 2024. Moreover, Exscientia’s financials show a year-over-year revenue increase and decreased R&D expenses due to strategic pipeline prioritization and improved operational efficiencies.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.
